Proceedings of International Conference on Applied Innovation in IT  ·  2026/03/31  ·  Vol. 14  ·  Issue 1  ·  pp. 893–899
Association Between Nesfatin-1 Levels and Obesity in Type 2 Diabetes Patients
Rusul Y. Hameed, Ekhlas Abdallah Hassan, Ali A. Taha and Donia A Abdulateef
📄 Download PDF DOI: 10.25673/123651
Abstract
One of the most serious consequences of obesity is Type 2 Diabetes mellitus. It has been linked to a chronic systemic inflammatory condition that plays a central role in insulin resistance associated with Type 2 Diabetes Mellitus. This study aimed to evaluate serum nesfatin-1 levels in patients with type 2 diabetes mellitus and to interpret these levels in relation to obesity, as measured by body mass index, and Homeostatic Model Assessment for Insulin Resistance). A total of 60 patients and 30 controls were recruited for this research. We assessed BMI, HOMA-IR, insulin levels, fasting plasma glucose. HbA1c, and serum nesfatin-1 concentrations for all participants. The serum insulin level (23.19 vs. 13.20 µIU/ml) and HOMA (13.50 vs. 2.12) were significantly elevated in patients compared to controls. Conversely, the nesfatin-1 level was notably lower in patients (55.12 ± 7.1 ng/ml vs. 79.03 ± 7.1 ng/ml). Receiver Operating Characteristic (ROC) analysis indicated significant variations in the following descending order: FPG (0.959), serum insulin (0.692), and serum nesfatin-1 (0.869). Furthermore, a significant negative correlation was observed between nesfatin-1 and obesity. When a multiple linear regression model was applied to examine the independent effects of BMI and HOMA, a significant negative correlation was found with nesfatin-1 levels. Additionally, the odds ratio (OR=33.3) indicated that the likelihood of having a high HOMA among patients was significantly increased with lower nesfatin-1 levels. In conclusion, lower nesfatin-1 levels are associated with a heightened risk of T2DM, particularly among obese individuals with diabetes.
Keywords
Obesity Type 2 Diabetes Mellitus Nesfatin-1 BMI HOMA-IR.
References
  1. G. Frühbeck and V. Yumuk, “Obesity: A gateway disease with a rising prevalence,” Obesity Facts, 2014, [Online]. Available: https://doi.org/10.1159/000361004.
  2. Y. Y. Chen et al., “The association of a nucleobindin 2 gene (NUCB2) variant with childhood adiposity,” Gene, vol. 516, no. 1, 2013, [Online]. Available: https://doi.org/10.1016/j.gene.2012.12.017.
  3. T. Kelly, W. Yang, C. S. Chen, K. Reynolds, and J. He, “Global burden of obesity in 2005 and projections to 2030,” International Journal of Obesity, vol. 32, no. 9, 2008, [Online]. Available: https://doi.org/10.1038/ijo.2008.102.
  4. D. R. Leitner et al., “Obesity and type 2 diabetes: Two diseases with a need for combined treatment strategies - EASO can lead the way,” Obesity Facts, vol. 10, no. 5, 2017, [Online]. Available: https://doi.org/10.1159/000480525.
  5. F. M. Khaleel, E. A. Hassan, and S. K. Mohammed, “Evaluation of serum zinc in women of childbearing age and its relationship with obesity,” Eurasian Chemical Communications, vol. 4, no. 10, 2022, [Online]. Available: https://doi.org/10.22034/ecc.2022.330219.1330.
  6. P. A. Dyson, “The therapeutics of lifestyle management on obesity,” 2010, [Online]. Available: https://doi.org/10.1111/j.1463-1326.2010.01256.x.
  7. E. A. Hassan, W. S. Al-Zuhairi, and A. I. Abdulmajeed, “The relation between homocysteine, oxidative stress and atherosclerosis disease,” Indian Journal of Public Health Research and Development, vol. 10, no. 7, 2019, [Online]. Available: https://doi.org/10.5958/0976-5506.2019.01626.7.
  8. G. A. Bray, “Risks of obesity,” 2003, [Online]. Available: https://doi.org/10.1016/S0889-8529(03)00067-7.
  9. A. Stengel and Y. Taché, “Role of brain NUCB2/nesfatin-1 in the regulation of food intake,” Current Pharmaceutical Design, vol. 19, no. 39, 2013, [Online]. Available: https://doi.org/10.2174/138161281939131127125735.
  10. S. M. Samani, H. Ghasemi, K. R. Bookani, and B. Shokouhi, “Serum nesfatin-1 level in healthy subjects with weight-related abnormalities and newly diagnosed patients with type 2 diabetes mellitus: A case-control study,” Acta Endocrinologica, vol. 15, no. 1, 2019, [Online]. Available: https://doi.org/10.4183/aeb.2019.69.
  11. A. Stengel, “Nesfatin-1 - More than a food intake regulatory peptide,” Peptides, vol. 72, 2015, [Online]. Available: https://doi.org/10.1016/j.peptides.2015.06.002.
  12. E. A. Hassan, R. Y. Hameed, and S. A. Mezil, “Impacts of androgen abuse and overtraining on endocrine profile in bodybuilders,” Iraqi Journal of Science, vol. 62, no. 12, 2021, [Online]. Available: https://doi.org/10.24996/ijs.2021.62.12.2.
  13. H. Van Minh et al., “Assessment of preferred methods to measure insulin resistance in Asian patients with hypertension,” 2021, [Online]. Available: https://doi.org/10.1111/jch.14155.
  14. F. Liu, Q. Yang, N. Gao, F. Liu, and S. Chen, “Decreased plasma nesfatin-1 level is related to the thyroid dysfunction in patients with type 2 diabetes mellitus,” Journal of Diabetes Research, vol. 2014, 2014, [Online]. Available: https://doi.org/10.1155/2014/128014.
  15. Q. C. Li, H. Y. Wang, X. Chen, H. Z. Guan, and Z. Y. Jiang, “Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans,” Regulatory Peptides, vol. 159, no. 1-3, 2010, [Online]. Available: https://doi.org/10.1016/j.regpep.2009.11.003.
  16. R. Wang, J. Wang, and X. Wan, “Association of the polymorphism in nucleobindin 2 gene and the risk of metabolic syndrome,” Genetic Testing and Molecular Biomarkers, vol. 20, no. 1, 2016, [Online]. Available: https://doi.org/10.1089/gtmb.2015.0194.
  17. M. Venkatrao, R. Nagarathna, V. Majumdar, S. S. Patil, S. Rathi, and H. Nagendra, “Prevalence of obesity in India and its neurological implications: A multifactor analysis of a nationwide cross-sectional study,” Annals of Neurosciences, vol. 27, no. 3-4, 2020, [Online]. Available: https://doi.org/10.1177/0972753120987465.
  18. N. Gray, G. Picone, F. Sloan, and A. Yashkin, “Relation between BMI and diabetes mellitus and its complications among US older adults,” Southern Medical Journal, vol. 108, no. 1, 2015, [Online]. Available: https://doi.org/10.14423/SMJ.0000000000000214.
  19. N. Mohammad and D. Gallaly, “Serum nesfatin-1 in patients with type 2 diabetes mellitus: A cross sectional study,” Zanco Journal of Medical Sciences, vol. 24, no. 1, 2020, [Online]. Available: https://doi.org/10.15218/zjms.2020.001.
  20. R. A. Matta, S. H. El-Hini, A. M. S. E. Salama, and H. M. Moaness, “Serum nesfatin-1 is a biomarker of pre-diabetes and interplays with cardiovascular risk factors,” Egyptian Journal of Internal Medicine, vol. 34, no. 1, 2022, [Online]. Available: https://doi.org/10.1186/s43162-022-00106-y.

Proceedings of the International Conference on Applied Innovations in IT by Anhalt University of Applied Sciences is licensed under CC BY-SA 4.0  ·  This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License

ICAIIT 2026
International Conference on Applied Innovation in IT
Navigation
Publisher
ISSN2199-8876
Publisher Edition Hochschule Anhalt
Location Anhalt University of Applied Sciences
Email leiterin.hsb@hs-anhalt.de
Phone +49 (0) 3496 67 5611
Address Building 01, Room 425
Bernburger Str. 55
D-06366 Köthen, Germany
Open Access License
CC BY-SA 4.0

All works are licensed under the Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA 4.0), unless otherwise noted.

Published by ICAIIT in cooperation with Anhalt University of Applied Sciences.

© 2026 ICAIIT — International Conference on Applied Innovations in IT. Anhalt University of Applied Sciences, Köthen, Germany.
Visitors: site traffic counter